Search
AspireAssist device
Indications:
- obesity, BMI >= 35 kg/m2 [1,2]
* more effective than counseling alone [2]
Procedure:
- endoscopic insertion of a tube into the stomach via a small incision in the abdomen
- a disk-shaped port valve that lies outside the body, flush against the skin of the abdomen, is connected to the tube & remains in place
- ~20-30 minutes after meal consumption, an external connector & tubing is attached to the port valve
- the port valve is opened & the contents drained into a toilet - this takes ~5-10 minutes [1]
Adverse effects:
- common
- peristomal granulation tissue
- non-specific abdominal pain
- dyspepsia
- serious
- peritonitis
- peptic ulcer
- tube malfunction [2]
Mechanism of action:
- surgically-placed tube to drain a portion of the stomach contents after every meal
- typically about 30% of ingested calories [2]
- BMI reduction of ~12% after 1 year [1]
General
device (medical device)
bariatric surgery
References
- FDA News Release. June 14, 2016
FDA approves AspireAssist obesity device.
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm506625.htm
- Thompson CC, Abu Dayyeh BK Kushner R et al.
Percutaneous gastrostomy device for the treatment of class II
and class III obesity: Results of a randomized controlled trial.
Am J Gastroenterol 2017 Mar; 112:447
PMID: 27922026